Menu
Recruiting NCT03980457

Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke

No phase Interventional Stroke Weakness of Extremities as Sequela of Stroke

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Indego Exoskeleton, Standard Rehabilitation.
Who it may be relevant to
Registry conditions: Stroke, Weakness of Extremities as Sequela of Stroke. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.

Detailed description

Abstract

Objective: The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.

Background:

Method: The investigators will study 50 patients with stroke consecutively admitted to a designated stroke rehabilitation unit in the Oklahoma City VA Medical Center. All patients will receive their daily 3-hours conventional therapy, plus an hour of either exoskeleton or over-ground gait training 3 times per week for 60 minutes. Patients were assigned to either the experimental (exoskeleton) or the control (over-ground) groups by computer-generated randomization. This is an open-label pragmatic trial, where neither the patients nor the clinicians could be masked to the intervention. Institution review board (IRB) approval will be obtained for the protocol. The demographic data to be collected includes: age, gender, race/ethnicity, stroke onset to admission, stroke types (ischemic/hemorrhagic), and stroke severity (on the National Institute of Health Stroke Severity \[NIHSS\] scale. Admission and discharge total Functional Independence Measure (FIM), spasticity and depression scores, ambulation velocity over 2-minutes (2-MWT) in feet/minute, and discharge disposition. The intervention is Indego® exoskeleton. The primary outcome measures were: changes in the FIM, depression and spasticity scores. The secondary outcome measure was discharge disposition. Continuous variables were analyzed using Students t-test, ordinal variables were analyzed using Mann-Whitney, and the nominal variables were analyzed using Chi-square analyses.

Interventions

  • Device Indego Exoskeleton
    Powered generated orthosis
  • Other Standard Rehabilitation
    Standard Rehabilitation

Primary outcome measures

  • The Functional Independence Measure (FIM™) [Time frame: Baseline (Day 1) and at 4-weeks to measure change]
  • The two minute walk test (2-MWT) [Time frame: Baseline (Day 1) and at 4-weeks to measure change]
Secondary outcome measures (3)
  • Modified Ashworth Scale (MAS) [Time frame: Baseline (Day 1) and at 4-weeks to measure change]
  • Discharge disposition [Time frame: 4-weeks]
  • The Beck Depression Inventory (BDI) [Time frame: Baseline (Day 1) and at 4-weeks to measure change]

Eligibility criteria

Inclusion criteria

  • All patients with acute hemorrhagic or ischemic stroke documented clinically and by neuroimaging.
  • Medically stable from a cardio-respiratory stand point so that they can participate in daily therapies.
  • Depressed patients will be included in the study
  • Patients able to stand alone
  • Patients able to provide a written informed consent, from cognitively intact patients (admission Mini Mental Scale Examination \[MMSE\] greater than or equal to 21).

Exclusion criteria

  • Aphasic patients unable to communicate
  • Confused patients
  • Patients medically unstable
  • Patients unable to stand alone
  • Refusal to provide written informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Oklahoma City VA Health Care System — Oklahoma City

Identifiers

NCT: NCT03980457 · 10742

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗